Kezar Life Sciences ends AIH program after FDA setback, begins strategic review

Kezar Life Sciences, Inc.

FDA cancelled Type C meeting for zetomipzomib in autoimmune hepatitis; requires PK study causing ~2-year delay and 48-hour in-unit monitoring.
Company to explore strategic alternatives, retain TD Cowen; restructuring includes workforce reduction and cost containment.
Preliminary cash, equivalents and marketable securities of $90.2M as of Sep 30, 2025 (unaudited).
Rights plan amended to extend expiration to after 2026 annual meeting (or 2027 if ratified); not in response to takeover threat.
PORTOLA final data still to be presented at The Liver Meeting Nov 10, 2025.

item 1.01 item 3.03 item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Kezar Life Sciences, Inc. issued securities.

Exact text from the filing

On October 16, 2025, the Company entered into Amendment No. 2 (the “Amendment”) to the Rights Agreement, dated as of October 17, 2024, as amended on December 3, 2024, by and between the Company and Computershare Trust Company, N.A., as rights agent (as amended, the “Rights Agreement”).

View on SEC.gov

32 equity issuances filed in the last 30 days. Browse all equity issuances →

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-045215

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.